NCT06722586 - Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Antiphospholipid (aPL)-PositiveThrombocytopaenia

Interventions

DRUG

Sirolimus

Sirolimus two pills (1mg) per day

DRUG

Placebo

Placebo two pills per day

Trial Locations (10)

100020

RECRUITING

Beijing Chao-Yang Hospital, Beijing

100034

RECRUITING

Peking University First Hospital, Beijing

100083

RECRUITING

Peking University Third Hospital, Beijing

200001

RECRUITING

Shanghai Renji Hospital, Shanghai

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

325015

RECRUITING

The 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou

410013

RECRUITING

Xiangya Hospital of Central South University, Changsha

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

830001

RECRUITING

People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi

Unknown

RECRUITING

Beijing Shijitan Hospital, Beijing